Aimee Wilkin to Treatment Outcome
This is a "connection" page, showing publications Aimee Wilkin has written about Treatment Outcome.
Connection Strength
0.147
-
Messer LC, Parnell H, Huffaker R, Wooldredge R, Wilkin A. The development of a health information exchange to enhance care and improve patient outcomes among HIV+ individuals in rural North Carolina. Int J Med Inform. 2012 Oct; 81(10):e46-55.
Score: 0.060
-
Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012 May; 28(5):437-46.
Score: 0.056
-
Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results. Antivir Ther. 2016; 21(1):55-64.
Score: 0.018
-
Townsend D, Troya J, Maida I, Pérez-Saleme L, Satta G, Wilkin A, Barreiro P, Pegram PS, Soriano V, Mura MS, Núñez M. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct; 8(5):314-7.
Score: 0.012